Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4585424
Max Phase: Preclinical
Molecular Formula: C27H31BrCl2N2O
Molecular Weight: 477.45
Molecule Type: Unknown
Associated Items:
ID: ALA4585424
Max Phase: Preclinical
Molecular Formula: C27H31BrCl2N2O
Molecular Weight: 477.45
Molecule Type: Unknown
Associated Items:
Canonical SMILES: Cl.Cl.OCCC/C(=C(\c1ccc(Br)cc1)c1ccc(N2CCNCC2)cc1)c1ccccc1
Standard InChI: InChI=1S/C27H29BrN2O.2ClH/c28-24-12-8-22(9-13-24)27(26(7-4-20-31)21-5-2-1-3-6-21)23-10-14-25(15-11-23)30-18-16-29-17-19-30;;/h1-3,5-6,8-15,29,31H,4,7,16-20H2;2*1H/b27-26-;;
Standard InChI Key: KSOHJXHZMVIUAY-ZNKLZGLFSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 477.45 | Molecular Weight (Monoisotopic): 476.1463 | AlogP: 5.59 | #Rotatable Bonds: 7 |
Polar Surface Area: 35.50 | Molecular Species: BASE | HBA: 3 | HBD: 2 |
#RO5 Violations: 1 | HBA (Lipinski): 3 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: | CX Basic pKa: 8.88 | CX LogP: 5.84 | CX LogD: 4.35 |
Aromatic Rings: 3 | Heavy Atoms: 31 | QED Weighted: 0.44 | Np Likeness Score: -0.37 |
1. Kim J, Song J, Ji HD, Yoo EK, Lee JE, Lee SB, Oh JM, Lee S, Hwang JS, Yoon H, Kim DS, Lee SJ, Jeong M, Lee S, Kim KH, Choi HS, Lee SW, Park KG, Lee IK, Kim SH, Hwang H, Jeon YH, Chin J, Cho SJ.. (2019) Discovery of Potent, Selective, and Orally Bioavailable Estrogen-Related Receptor-γ Inverse Agonists To Restore the Sodium Iodide Symporter Function in Anaplastic Thyroid Cancer., 62 (4): [PMID:30657313] [10.1021/acs.jmedchem.8b01296] |
Source(1):